Thera-SAbDab

(Therapeutic Structural Antibody Database)

Search results

473 therapeutic(s) match your criteria. Click on the therapeutic name to open a summary page.
[NFD = No Further Development, (w) = Withdrawn, Semicolons delimit separate variable domains for bispecifics]
Click a column heading to sort by that attribute (may take a couple of seconds if the table contains many entries)

TherapeuticFormatHighest Clinical Trial (June '19)Est. Status (June '19)TargetYear Proposed100% SI Struc.99% SI Struc.95-98% SI Struc.
abagovomabWhole mAbPhase-IIIDiscontinuedCA1252006nonono
abelacimabWhole mAbUnknownUnknownF112018nonoYES
abituzumabWhole mAbPhase-IIActiveITGAV2013nonono
abrezekimabFabPhase-IDiscontinuedIL132017nonono
abrilumabWhole mAbPhase-IIDiscontinuedα4β72014nonono
actoxumabWhole mAbPhase-IIIActivetoxin A2012nonono
adalimumabWhole mAbApprovedActiveTNFA1999YESYESno
aducanumabWhole mAbPhase-IIIDiscontinuedAPP2013YESnono
afasevikumabWhole mAbPhase-IActiveIL17A2015nonono
afutuzumabWhole mAbApprovedActiveMS4A12008YESnono
alacizumabdi-FabPhase-IIDiscontinuedKDR2007nonono
alemtuzumabWhole mAbApprovedActiveCD522000YESnono
alirocumabWhole mAbApprovedActivePCSK92012nonono
amatuximabWhole mAbPhase-IIActiveMSLN2010noYESno
andecaliximabWhole mAbPhase-IIIActiveMMP92016YESnono
anetumabWhole mAb ADCPhase-IIActiveMSLN2013nonono
anifrolumabWhole mAbPhase-IIIActiveIFNAR12013YESnono
anrukinzumabWhole mAbPhase-IIDiscontinuedIL132007nonono
apamistamabWhole mAb RadiolabelledPhase-IIIActivePTPRC2018nonono
aprutumabWhole mAb ADCPhase-IDiscontinuedFGFR22016nonono
ascrinvacumabWhole mAbPhase-IIActiveACVRL12015nonono
atezolizumabWhole mAbApprovedActiveCD2742014YESYESno
atidortoxumabWhole mAbPhase-IIDiscontinuedtoxin A2017nonono
atinumabWhole mAbPhase-IDiscontinuedRTN42010nonono
atoltivimabWhole mAbPreclinicalDiscontinuedZaire Ebolavirus GP2018nonono
avelumabWhole mAbApprovedActiveCD2742015YESnono
azintuxizumabWhole mAb ADCPhase-IDiscontinuedSLAMF72016nonono
balstilimabWhole mAbUnknownActivePDCD12018nonono
bapineuzumabWhole mAbPhase-IIDiscontinuedAPP2005nonoYES
basiliximabWhole mAbApprovedNFDIL2RA1996YESnono
bavituximabWhole mAbPhase-IIIActivePhosphatidylserine2006nonono
bedinvetmabCanine Whole mAbUnknownActiveCanine NGFB2018nonono
begelomabWhole mAbPhase-II/IIIActiveDPP42014nonono
belantamabWhole mAb ADCPhase-IActiveTNFRSF172017nonono
belimumabWhole mAbApprovedActiveTNFSF13B2003YESnoYES
bemarituzumabWhole mAbPhase-IIIActiveFGFR22017nonono
benralizumabWhole mAbApprovedActiveIL5RA2009nonono
berlimatoxumabWhole mAbPhase-IIDiscontinuedtoxin A2017YESnono
bermekimabWhole mAbPreregistrationActiveIL1A2018nonono
bersanlimabWhole mAbPhase-IIDiscontinuedICAM12017nonono
bevacizumabWhole mAbApprovedActiveVEGFA2000YESnoYES
bezlotoxumabWhole mAbApprovedNFDtoxin A2012YESnono
bifikafuspdi-scFv + CH4Phase-IIActiveFN extra domain B2010nonono
bimagrumabWhole mAbPhase-IIActiveACVR2B2012YESYESno
bimekizumabWhole mAbPhase-IIIActiveIL17A2013nonono
birtamimabWhole mAbPhase-IIIDiscontinuedSAA12018nonono
bleselumabWhole mAbPhase-IIActiveCD402015nonono
blinatumomabBispecific T-Cell EngagerApprovedActiveCD19;CD3E2008no;nono;nono;no
blontuvetmabCanine Whole mAbUnknownActiveMS4A12015nonono
blosozumabWhole mAbPhase-IIActiveSOST2011nonono
bococizumabWhole mAbPhase-IIIDiscontinuedPCSK92013YESnono
brazikumabWhole mAbPhase-II/IIIActiveIL23A2016nonono
brentuximabWhole mAb ADCApprovedActiveTNFRSF82010nonono
briakinumabWhole mAbPreregistration (w)DiscontinuedIL12B2009YESnono
brodalumabWhole mAbApprovedActiveIL17RA2011nonono
brolucizumabscFvPreregistrationActiveVEGFA2014nonono
brontictuzumabWhole mAbPhase-IActiveNOTCH12014nonono
budigalimabWhole mAbPhase-IActivePDCD12018nonono
burosumabWhole mAbApprovedActiveFGF232016nonono
cabiralizumabWhole mAbPhase-IIActiveCSF1R2015nonono
camidanlumabWhole mAb ADCPhase-IActiveIL2RA2017nonono
camrelizumabWhole mAbPreregistrationActivePDCD12016nonono
canakinumabWhole mAbApprovedActiveIL1B2007noYESno
cantuzumabWhole mAb ADCPhase-IIDiscontinuedMUC12003nonono
caplacizumabNanobodyApprovedNFDVWF2011nonono
carlumabWhole mAbPhase-IIDiscontinuedCCL22010noYESno
carotuximabWhole mAbPhase-IIIActiveENG2015nonono
cemiplimabWhole mAbApprovedActivePDCD12018nonono
cendakimabWhole mAbUnknownActiveIL132018nonono
cergutuzumabWhole mAb FusionPhase-IDiscontinuedCEACAM52015nonono
certolizumabFabApprovedActiveTNFA2004YESnono
cetrelimabWhole mAbPhase-II/IIIActivePDCD12017nonono
cetuximabWhole mAbApprovedActiveEGFR1999YESYESYES
cibisatamabBispecific mAb with Domain CrossoverPhase-I/IIActiveCEACAM5&CD3E;CD3E2017no;nono;nono;no
cinpanemabWhole mAbPhase-IIActiveSNCA2018YESnono
citatuzumabFab FusionPhase-IActiveEPCAM2008nonono
cixutumumabWhole mAbPhase-IIDiscontinuedIGF1R2008nonono
claudiximabWhole mAbPhase-IIIActiveCLDN182017nonono
clazakizumabWhole mAbPhase-IIActiveIL62012nonono
clervonafuspdi-Fab FusionPhase-I/IIActiveSLC29A22018nonono
clivatuzumabWhole mAb RadiolabelledPhase-IIIDiscontinuedMUC12009nonono
cobolimabWhole mAbPhase-IIActiveHAVCR22018nonono
codrituzumabWhole mAbPhase-IIActiveGPC32013nonono
cofetuzumabWhole mAb ADCPhase-IActivePTK72017nonono
coltuximabWhole mAb ADCPhase-IIActiveCD192013YESnono
conatumumabWhole mAbPhase-IIDiscontinuedTNFRSF10B2008nonono
concizumabWhole mAbPhase-IIActiveTFPI2012YESnono
cosfroviximabWhole mAbPhase-IIActiveZaire Ebolavirus GP2016nonono
crenezumabWhole mAbPhase-IIIActiveAPP2011YESYESno
crizanlizumabWhole mAbPhase-IIIActiveSELP2016nonono
crotedumabWhole mAbPhase-IDiscontinuedGCGR2015nonono
crovalimabWhole mAbPhase-I/IIActiveC52018YESnono
cusatuzumabWhole mAbPhase-IIActiveCD702017nonono
dacetuzumabWhole mAbPhase-IIDiscontinuedCD402007nonono
daclizumabWhole mAbApprovedActiveIL2RA1994YESnono
dalotuzumabWhole mAbPhase-IIActiveIGF1R2009nonono
dapirolizumabFabPhase-IIActiveCD40LG2013nonono
daratumumabWhole mAbApprovedActiveCD382009nonono
dectrekumabWhole mAbPhase-IIDiscontinuedIL132014nonono
demcizumabWhole mAbPhase-IDiscontinuedDLL42012nonono
denintuzumabWhole mAb ADCPhase-IIDiscontinuedCD192014nonono
denosumabWhole mAbApprovedActiveTNFSF112005nonono
depatuxizumabWhole mAb ADCPhase-IIIDiscontinuedEGFR2016nonono
derlotuximabWhole mAb RadiolabelledApprovedActiveDNA/H1 Complex2015nonono
dezamizumabWhole mAbPhase-IIActiveAPCS2016nonono
dilpacimabBispecific mAbPhase-IIActiveVEGFA;DLL42018no;YESno;nono;YES
dinutuximabWhole mAbApprovedActiveGanglioside GD22013nonoYES
diridavumabWhole mAbPhase-IIActiveInfluenza A HA22014YESnoYES
disitamabWhole mAb ADCPhase-IIActiveERBB22018nonono
domagrozumabWhole mAbPhase-IIActiveMSTN2015noYESno
donanemabWhole mAbPhase-IIActiveAPP2018nonono
dostarlimabWhole mAbPhase-IIIActivePDCD12018nonono
drozitumabWhole mAbPhase-IIDiscontinuedTNFRSF10B2010YESnono
duligotuzumabWhole mAbPhase-IIDiscontinuedERBB32012nonoYES
dupilumabWhole mAbApprovedActiveIL4R2012nonono
durvalumabWhole mAbApprovedActiveCD2742014YESnono
dusigitumabWhole mAbPhase-IIDiscontinuedIGF1&IGF22012nonono
duvortuxizumabBispecific scFv with CrossoverPhase-IDiscontinuedCD19;CD3E2016no;nono;nono;no
eculizumabWhole mAbApprovedActiveC52002YESnono
edrecolomabWhole mAbApproved (w)DiscontinuedEPCAM1995nonono
efalizumabWhole mAbApprovedNFDITGAL2001YESnono
efungumabscFvPhase-IIIDiscontinuedHeat Shock Protein 90 Homolog2006nonono
eldelumabWhole mAbPhase-IIDiscontinuedCXCL102013nonono
elezanumabWhole mAbPhase-IIActiveRGMA2016nonono
elgemtumabWhole mAbPhase-I/IIDiscontinuedERBB32014nonoYES
elipovimabWhole mAbUnknownActiveHIV-1 gp1202018nonoYES
elotuzumabWhole mAbApprovedNFDSLAMF72008nonono
emactuzumabWhole mAbPhase-IIActiveCSF1R2014YESnono
emapalumabWhole mAbApprovedNFDIFNG2016nonono
emibetuzumabWhole mAbPhase-IIActiveMET2014nonono
emicizumabBispecific mAbApprovedNFDF9;F102015no;nono;nono;no
enapotamabWhole mAb ADCPhase-IIActiveAXL2017nonono
enavatuzumabWhole mAbPhase-IDiscontinuedTNFRSF12A2010nonono
enfortumabWhole mAb ADCPhase-IIIActivePVRL42013nonono
enoblituzumabWhole mAbPhase-IIActiveCD2762015nonono
enokizumabWhole mAbPhase-IIDiscontinuedIL92010nonono
enoticumabWhole mAbPhase-IDiscontinuedDLL42012nonono
ensituximabWhole mAbPhase-IIActiveMUC5AC2010nonono
envafolimabSingle Domain Variable Fragment;HUnknownActivePDL12018nonono
epratuzumabWhole mAbPhase-IIIDiscontinuedCD221999noYESno
eptinezumabWhole mAbPreregistrationActiveCALCA&CALCB2016nonono
erenumabWhole mAbApprovedNFDCALCRL2016nonono
etaracizumabWhole mAbPhase-IIDiscontinuedITGAV_ITGB32008nonono
etigilimabWhole mAbPhase-IActiveTIGIT2017nonono
etokimabWhole mAbPhase-IIActiveIL132018nonono
etrolizumabWhole mAbPhase-IIIActiveITGA4_ITGB7&ITGAE_ITGB72010nonono
evinacumabWhole mAbPhase-IIIActiveANGPTL32014nonono
evolocumabWhole mAbApprovedActivePCSK92012nonono
faricimabBispecific mAbPhase-IIIActiveVEGFA;ANGPT22017YES;nono;noYES;YES
farletuzumabWhole mAbPhase-IIIActiveFOLR12008nonono
fasinumabWhole mAbPhase-IIIActiveNGFB2012nonono
fezakinumabWhole mAbPhase-IDiscontinuedIL222009nonono
ficlatuzumabWhole mAbPhase-IIActiveHGF2011nonono
figitumumabWhole mAbPhase-IDiscontinuedIGF1R2008nonono
firivumabWhole mAbPreclinicalDiscontinuedInfluenza A HA2014nonono
flanvotumabWhole mAbPhase-IDiscontinuedTYRP12011nonono
fletikumabWhole mAbPhase-IIDiscontinuedIL202013nonono
flotetuzumabBispecific scFv with CrossoverPhase-IActiveCD3E;IL3RA2017no;nono;nono;no
fontolizumabWhole mAbPhase-IIDiscontinuedIFNG2002noYESno
foralumabWhole mAbPhase-IIActiveCD3E2010nonono
foravirumabWhole mAbPhase-IIDiscontinuedRV Antigenic Site III2008nonono
fremanezumabWhole mAbApprovedActiveCALCA&CALCB2016nonono
fresolimumabWhole mAbPhase-IActiveTGFB2009YESnono
frovocimabWhole mAbPhase-IIActivePCSK92018nonono
frunevetmabFeline Whole mAbUnknownActiveNGFB2016nonono
fulranumabWhole mAbPhase-IIIDiscontinuedNGFB2010YESnono
futuximabWhole mAbPhase-IIActiveEGFR2012nonono
galcanezumabWhole mAbApprovedActiveCALCA&CALCB2015nonono
galiximabWhole mAbPhase-IIDiscontinuedCD802003nonono
gancotamabscFvPhase-IIDiscontinuedERBB22018nonono
ganitumabWhole mAbPhase-IIIActiveIGF1R2010nonono
gantenerumabWhole mAbPhase-IIIActiveAPP2012YESnono
garadacimabWhole mAbUnknownActiveF122018nonono
garetosmabWhole mAbPhase-IIActiveINHBA2018nonono
gatipotuzumabWhole mAbPhase-IIActiveMUC12016nonono
gedivumabWhole mAbPhase-IIActiveInfluenza A HA2016nonoYES
gemtuzumabWhole mAb ADCApprovedNFDCD332016nonono
gevokizumabWhole mAbPhase-IIIActiveIL1B2010YESnono
gilvetmabCanine Whole mAbUnknownActivePDCD1 (Canine)2016nonono
gimsilumabWhole mAbPhase-IDiscontinuedCSF22017nonono
girentuximabWhole mAb RadiolabelledPhase-IIIDiscontinuedCA92009nonono
glembatumumabWhole mAb ADCPhase-IIIDiscontinuedGPNMB2015nonono
glenzocimabFabUnknownActiveGP62018nonono
golimumabWhole mAbApprovedActiveTNFA2004YESnono
gosuranemabWhole mAbPhase-IIActiveMAPT2018nonono
guselkumabWhole mAbApprovedActiveIL23A2013YESnono
ianalumabWhole mAbPhase-II/IIIActiveTNFRSF13C2017nonono
ibalizumabWhole mAbApprovedNFDCD42007YESnono
icrucumabWhole mAbPhase-IIActiveFLT12010nonono
idarucizumabFabApprovedNFDDabigatran2013YESnono
ieramilimabWhole mAbUnknownActiveCD2232018nonono
ifabotuzumabWhole mAbPhase-IIActiveEPHA32015nonono
iladatuzumabWhole mAb ADCPhase-IDiscontinuedCD79B2017nonono
imalumabWhole mAbPhase-IIActiveMIF2014YESnono
imaprelimabWhole mAbPhase-IDiscontinuedMCAM2017nonono
imgatuzumabWhole mAbPhase-IIDiscontinuedEGFR2012nonono
inclacumabWhole mAbPhase-IIActiveSELP2011nonono
indatuximabWhole mAb ADCPhase-IIActiveSDC12011nonono
indusatumabWhole mAb ADCPhase-IIDiscontinuedGUCY2C2014nonono
inebilizumabWhole mAbPhase-II/IIIActiveCD192015nonono
infliximabWhole mAbApprovedNFDTNFA1997YESnono
inotuzumabWhole mAb ADCApprovedActiveCD222004nonono
intetumumabWhole mAbPhase-IIDiscontinuedITGAV_ITGB32009nonono
ipilimumabWhole mAbApprovedActiveCTLA42005YESnono
iratumumabWhole mAbPhase-IIDiscontinuedTNFRSF82005nonono
isatuximabWhole mAbPhase-IIIActiveCD382014YESnono
iscalimabWhole mAbPhase-IIActiveCD402017nonono
istiratumabBispecific Mixed mAb and scFvPhase-IIDiscontinuedIGF1R;ERBB32017no;nono;nono;no
itolizumabWhole mAbApprovedActiveCD62010nonono
ixekizumabWhole mAbApprovedActiveIL17A2011YESYESno
labetuzumabWhole mAb ADCPhase-IIActiveCEACAM52015nonono
lacnotuzumabWhole mAbPhase-IIActiveCSF12016nonono
lacutamabWhole mAbUnknownActiveKIR3DL22018nonono
ladiratuzumabWhole mAb ADCPhase-IIActiveSLC39A62017nonono
lambrolizumabWhole mAbApprovedActivePDCD12013YESnono
lampalizumabFabPhase-IIIDiscontinuedCFD2012YESnono
lanadelumabWhole mAbApprovedNFDKLKB12015YESnono
landogrozumabWhole mAbPhase-IIActiveMSTN2015nonono
laprituximabWhole mAb ADCPhase-IDiscontinuedEGFR2015nonono
larcaviximabWhole mAbPhase-IIActiveZaire Ebolavirus GP2016nonono
lebrikizumabWhole mAbPhase-IIActiveIL132009YESnono
lenvervimabWhole mAbPhase-II/IIIActiveHBV2017nonono
lenzilumabWhole mAbPhase-I/IIActiveCSF22014nonono
leronlimabWhole mAbPreregistrationActiveCCR52017nonono
lesofavumabWhole mAbPhase-IDiscontinuedInfluenza B Virus2016nonono
letolizumabSingle Domain Variable Fragment;HPhase-I/IIActiveCD40LG2016nonono
levilimabWhole mAbUnknownActiveIL6R2018nonono
lexatumumabWhole mAbPhase-IDiscontinuedTNFRSF10B2006nonoYES
lifastuzumabWhole mAb ADCPhase-IIDiscontinuedSLC34A22013nonono
ligelizumabWhole mAbPhase-IIIActiveIGHE2012nonono
lilotomabWhole mAb ADCPhase-IIActiveCD372014nonono
lintuzumabWhole mAb RadiolabelledPhase-IIDiscontinuedCD331996nonono
lirilumabWhole mAbPhase-IIActiveKIRD22012nonono
lodelcizumabWhole mAbPhase-IIDiscontinuedPCSK92012nonono
lokivetmabCanine Whole mAbApprovedNFDIL312014nonono
loncastuximabWhole mAb ADCPhase-IIActiveCD192017noYESno
lorukafuspWhole mAb FusionPhase-IIActiveGanglioside GD22018nonoYES
lorvotuzumabWhole mAb ADCPhase-IIActiveNCAM12010nonono
losatuxizumabWhole mAb ADCPhase-IActiveEGFR2016nonono
lucatumumabWhole mAbPhase-IDiscontinuedCD402007nonono
lulizumabSingle Domain Variable Fragment;LPhase-IIActiveCD282014nonono
lumiliximabWhole mAbPhase-IIDiscontinuedFCER22004noYESno
lumretuzumabWhole mAbPhase-I/IIActiveERBB32014YESnono
lupartumabWhole mAb ADCPhase-IActiveLYPD32016nonono
lutikizumabBispecific Dual Variable Domain IGPhase-IIDiscontinuedIL1A;IL1B2016no;nono;nono;no
maftivimabWhole mAbPreclinicalDiscontinuedZaire Ebolavirus GP2018nonono
magrolimabWhole mAbUnknownActiveCD472018noYESno
margetuximabWhole mAbPhase-IIIActiveERBB22013nonono
marstacimabWhole mAbPhase-IIActiveERBB22013nonono
matuzumabWhole mAbPhase-IIDiscontinuedEGFR2003YESYESno
mavrilimumabWhole mAbPhase-IIActiveCSF2RA2009nonono
mepolizumabWhole mAbApprovedActiveIL51999nonono
milatuzumabWhole mAbPhase-I/IIActiveCD742007nonono
mirikizumabWhole mAbPhase-IIIActiveIL23A2017nonono
mirvetuximabWhole mAb ADCPhase-IIIActiveFOLR12015nonono
mitazalimabWhole mAbPhase-IActiveCD402017nonono
modotuximabWhole mAbPhase-IIActiveEGFR2012nonono
mogamulizumabWhole mAbApprovedActiveCCR42010nonono
monalizumabWhole mAbPhase-IIActiveKLRC12015nonono
mosunetuzumabBispecific mAbPhase-I/IIActiveCD3E;MS4A12017no;nono;nono;YES
motavizumabWhole mAbPhase-IIIDiscontinuedRSV gpF2006YESYESno
moxetumomabFv FusionApprovedNFDCD222009nonono
murlentamabWhole mAbPhase-IIActiveAMHR22018nonono
muromonabWhole mAbApprovedDiscontinuedCD3E1988YESnono
namilumabWhole mAbPhase-IIActiveCSF22010nonono
naptumomabFab FusionPhase-IIIDiscontinuedTPBG2006nonono
naratuximabWhole mAb ADCPhase-IIActiveCD372015nonono
narnatumabWhole mAbPhase-IDiscontinuedMST1R2011nonono
natalizumabWhole mAbApprovedActiveITGA41998noYESno
navicixizumabBispecific mAbPhase-IActiveDLL4;VEGFA2015no;nono;nono;no
navivumabWhole mAbPreclinicalDiscontinuedInfluenza A HA2015YESnono
naxitamabWhole mAbPhase-IIIActiveGanglioside GD22018nonono
necitumumabWhole mAbApprovedActiveEGFR2008YESnono
nemolizumabWhole mAbPhase-IIIActiveIL31RA2014nonono
nesvacumabWhole mAbPhase-IDiscontinuedANGPT22012nonono
netakimabWhole mAbPhase-IActiveIL17A2017nonono
nidanilimabWhole mAbPhase-IIActiveIL1RAP2018nonono
nimacimabWhole mAbPhase-IActiveCNR12018nonono
nimotuzumabWhole mAbApprovedActiveEGFR2005YESnono
nirsevimabWhole mAbPhase-II/IIIActiveRSV2018YESnoYES
nivolumabWhole mAbApprovedActivePDCD12012YESnono
obexelimabWhole mAbPhase-IIActiveCD192018nonono
obiltoxaximabWhole mAbApprovedNFDAnthrax Protective Antigen2015nonono
obinutuzumabWhole mAbApprovedActiveMS4A12008YESnono
ocaratuzumabWhole mAbPhase-IIDiscontinuedMS4A12012nonono
ocrelizumabWhole mAbApprovedNFDMS4A12005nonoYES
ofatumumabWhole mAbApprovedActiveMS4A12005YESnono
olaratumabWhole mAbApprovedActivePDGFRA2010nonono
oleclumabWhole mAbPhase-IIActiveNT5E2016nonono
olendalizumabWhole mAbPhase-IIActiveC52015nonono
olinvacimabWhole mAbPhase-IIActiveKDR2018nonono
olokizumabWhole mAbPhase-IIIActiveIL62010YESnono
omalizumabWhole mAbApprovedActiveIGHE2000YESYESno
omburtamabWhole mAb RadiolabelledPhase-II/IIIActiveCD2762018YESnono
onartuzumabFab + di-FcPhase-IIIDiscontinuedMET2010YESnono
onfekafuspdi-scFv + CH4Phase-IIActiveFN extra domain B2010nonono
ontamalimabWhole mAbPhase-IIIActiveMADCAM12018YESnono
ontuxizumabWhole mAbPhase-IIActiveCD2482013nonono
onvatilimabWhole mAbPhase-IDiscontinuedVSIR2017nonono
opicinumabWhole mAbPhase-IIActiveLINGO12015YESnono
oportuzumabscFvPhase-IIIActiveEPCAM2008nonono
orilanolimabWhole mAbPhase-IIActiveFCGRT2018nonono
orticumabWhole mAbPhase-IIActiveoxLDL2012nonono
osocimabWhole mAbPhase-IIActiveF112018nonono
otelixizumabWhole mAbPhase-IIActiveCD3E2007nonono
otilimabWhole mAbPhase-IIActiveCSF22018YESnoYES
otlertuzumabdi-scFv + FcPhase-IIDiscontinuedCD372013nonono
oxelumabWhole mAbPhase-IIDiscontinuedTNFSF42010nonono
ozanezumabWhole mAbPhase-IIDiscontinuedRTN42012nonono
ozoralizumabBispecific Single Domains (VH-VH'-VH)Phase-IIIActiveTNFA;ALB2011no;nono;noYES;no
pabinafuspWhole mAb FusionPhase-IIIActiveTFRC2018nonono
palivizumabWhole mAbApprovedNFDRSV gpF1998noYESno
pamrevlumabWhole mAbPhase-IIActiveCTGF2015nonono
panitumumabWhole mAbApprovedActiveEGFR2004YESnono
panobacumabWhole mAbPhase-IIActiveserotype IATS O112008nonono
parsatuzumabWhole mAbPhase-IIDiscontinuedEGFL72012nonono
pasotuxizumabBispecific scFvPhase-IDiscontinuedFOLH1;CD3E2014no;nono;nono;no
pateclizumabWhole mAbPhase-IIDiscontinuedLTA2011YESnono
patritumabWhole mAbPhase-IIIActiveERBB32011nonono
pembrolizumabWhole mAbApprovedActivePDCD12013YESnono
pepinemabWhole mAbPhase-IIActiveSEMA4D2018nonono
perakizumabWhole mAbPhase-IDiscontinuedIL17A2012nonono
pertuzumabWhole mAbApprovedActiveERBB22003YESYESYES
pidilizumabWhole mAbPhase-IIActivePDCD12012nonono
pinatuzumabWhole mAb ADCPhase-IIDiscontinuedCD222012noYESno
plamotamabBispecific Mixed mAb and scFvPhase-IActiveMS4A1;CD3E2018no;nono;nono;no
plozalizumabWhole mAbPhase-IIActiveCCR22015nonono
pogalizumabWhole mAbPhase-IIActiveTNFRSF42015YESnono
polatuzumabWhole mAb ADCPreregistrationActiveCD79B2012nonono
ponezumabWhole mAbPhase-IIDiscontinuedAPP2010YESnono
porgaviximabWhole mAbPhase-IIActiveZaire Ebolavirus GP2016nonono
prasinezumabWhole mAbPhase-IIActiveSNCA2017nonono
prezalumabWhole mAbPhase-IIDiscontinuedICOSLG2015nonono
pritoxaximabWhole mAbPhase-IIDiscontinuedShiga Toxin Type 12012nonono
prolgolimabWhole mAbPhase-II/IIIActivePDCD12018nonono
quetmolimabWhole mAbPhase-IIActiveCX3CL12018nonono
quilizumabWhole mAbPhase-IIDiscontinuedIGHE2011YESnono
racotumomabWhole mAbApprovedActiveIdiotope of anti-NeuGc-ganliosides2008nonono
radretumabdi-scFv + CH4Phase-IIActiveFN extra domain B2010nonono
rafivirumabWhole mAbPhase-IIDiscontinuedRV Antigenic Site III2008nonono
ralpancizumabWhole mAbPhase-IDiscontinuedPCSK92013nonoYES
ramucirumabWhole mAbApprovedActiveKDR2008YESnono
ranevetmabCanine Whole mAbUnknownActiveNGFB2016nonono
ranibizumabFabApprovedActiveVEGFA2004YESnoYES
ravagalimabWhole mAbPhase-IIActiveCD402017nonono
ravulizumabWhole mAbApprovedActiveC52017noYESno
refanezumabWhole mAbPhase-IIDiscontinuedMAG2015nonono
relatlimabWhole mAbPhase-II/IIIActiveLAG32018nonono
relfovetmabFeline Whole mAbUnknownActiveNGFB2018nonono
remtolumabBispecific Dual Variable Domain IGPhase-IIActiveTNFA;IL17A2016YES;noYES;nono;no
reslizumabWhole mAbApprovedActiveIL52001nonono
rilotumumabWhole mAbPhase-IIDiscontinuedHGF2009nonono
rinucumabWhole mAbPhase-IIDiscontinuedPDGFRB2015nonono
risankizumabWhole mAbApprovedActiveIL23A2015nonono
rituximabWhole mAbApprovedActiveMS4A11997YESYESno
rivabazumabFabPhase-IIActivePcrV type III secretion system2015nonono
robatumumabWhole mAbPhase-IIDiscontinuedIGF1R2008nonono
roledumabWhole mAbPhase-IIActiveRHD2010nonono
rolinsatamabWhole mAb ADCPhase-IActivePRLR2018nonono
romilkimabBispecific Dual Variable Domain IGPhase-IIActiveIL13;IL42017no;nono;nono;no
romosozumabWhole mAbApprovedNFDSOST2011nonono
rontalizumabWhole mAbPhase-IIDiscontinuedIFNA12009YESnono
rosmantuzumabWhole mAbPhase-IActiveRSPO32016nonono
rovalpituzumabWhole mAb ADCPhase-IIIActiveDLL32015nonono
rozanolixizumabWhole mAbPhase-IIActiveFCGRT2016YESnono
rozipafuspWhole mAb FusionPhase-IActiveICOS2018nonono
ruplizumabWhole mAbPhase-IIDiscontinuedCD40LG2000YESnono
sacituzumabWhole mAb ADCPreregistrationActiveTACSTD22016nonono
samalizumabWhole mAbPhase-IDiscontinuedCD2002010nonono
samrotamabWhole mAb ADCPhase-IActiveLRRC152017nonono
sapelizumabWhole mAbPhase-IIIActiveIL6R2015nonono
sarilumabWhole mAbApprovedActiveIL6R2011nonono
satralizumabWhole mAbPhase-IIIActiveIL6R2015nonono
secukinumabWhole mAbApprovedActiveIL17A2009nonono
selicrelumabWhole mAbPhase-IActiveCD402016nonono
semorinemabWhole mAbPhase-IIActiveMAPT2018nonono
serclutamabWhole mAb ADCPhase-IActiveEGFR2016nonono
seribantumabWhole mAbPhase-IIDiscontinuedERBB32012nonono
setoxaximabWhole mAbPhase-IIDiscontinuedShiga Toxin Type 22012nonono
setrusumabWhole mAbPhase-IIActiveSOST2017nonono
sifalimumabWhole mAbPhase-IIDiscontinuedIFNA12009YESnono
siltuximabWhole mAbApprovedActiveIL62008nonono
simtuzumabWhole mAbPhase-IIDiscontinuedLOXL22012nonono
sintilimabWhole mAbApprovedActivePDCD12018nonono
sirtratumabWhole mAb ADCPhase-IActiveSLITRK62017nonono
sirukumabWhole mAbPhase-IIIActiveIL62011nonono
sofituzumabWhole mAb ADCPhase-IDiscontinuedMUC162013nonono
solanezumabWhole mAbPhase-IIIActiveAPP2008noYESno
solitomabBispecific scFvPhase-IDiscontinuedEPCAM;CD3E2011no;nono;nono;no
spartalizumabWhole mAbPhase-IIIActivePDCD12017nonono
spesolimabWhole mAbPhase-II/IIIActiveIL36RN2018nonono
suptavumabWhole mAbPhase-IIIDiscontinuedRSV gpF2016nonono
sutimlimabWhole mAbPhase-IIIActiveC1S2017nonono
suvizumabWhole mAbPhase-IDiscontinuedHIV-1 gp1202009YESnono
suvratoxumabWhole mAbPhase-IIActivetoxin A2016YESnono
tabalumabWhole mAbPhase-IIIDiscontinuedTNFSF13B2011nonono
tabituximabWhole mAb ADCPhase-IDiscontinuedFZD102018nonono
tadocizumabFabPhase-IIDiscontinuedITGA2B_ITGB32005nonono
tafasitamabWhole mAbPhase-IIIActiveCD192018nonono
talacotuzumabWhole mAbPhase-IIIActiveIL3RA2017YESnono
tamrintamabWhole mAb ADCPhase-IActiveDPEP32018nonono
tamtuvetmabCanine Whole mAbUnknownActiveCD522015nonoYES
tanezumabWhole mAbPhase-IIIActiveNGFB2008YESnono
tanibirumabWhole mAbPhase-IIActiveKDR2018nonono
tarextumabWhole mAbPhase-IIActiveNOTCH2&32013nonono
tavolimabWhole mAbPhase-IIDiscontinuedTNFSF42016nonono
tavolixizumabWhole mAbPhase-IIDiscontinuedTNFSF42016nonono
tebentafuspscFv FusionPhase-IIActiveCD3E2017nonono
teclistamabBispecific mAbPhase-IActiveTNFRSF17;CD3E2018no;nono;nono;no
telisotuzumabWhole mAb ADCPhase-IDiscontinuedMET2016nonono
temelimabWhole mAbPhase-IIActiveMRSV envelope protein2018nonono
tenatumomabWhole mAb RadiolabelledPhase-IDiscontinuedTNC2007nonono
teplizumabWhole mAbPhase-IIIActiveCD3E2007nonono
tepoditamabBispecific mAbPhase-IActiveCLEC12A;CD3E2017no;nono;nono;no
teprotumumabWhole mAbPhase-IIIActiveIGF1R2009nonono
tesidolumabWhole mAbPhase-IIActiveC52014nonono
tezepelumabWhole mAbPhase-IIIActiveTSLP2015YESnono
tibulizumabBispecific Mixed mAb and scFvPhase-IActiveTNFSF13B;IL17A2017no;nono;nono;YES
ticilimumabWhole mAbPhase-IIIActiveCTLA42005YESnono
tidutamabBispecific Mixed mAb and scFvPhase-IActiveSSTR2;CD3E2018no;nono;nono;no
tigatuzumabWhole mAbPhase-IIDiscontinuedTNFRSF10B2007nonono
tilavonemabWhole mAbPhase-IIActiveMAPT2018nonono
tildrakizumabWhole mAbApprovedActiveIL23A2012nonono
timigutuzumabWhole mAbApprovedNFDERBB21997YESYESYES
timolumabWhole mAbPhase-IIActiveAOC32015nonono
tiragolumabWhole mAbPhase-IIActiveTIGIT2017nonono
tislelizumabWhole mAbPreregistrationActivePDCD12017nonono
tisotumabWhole mAbPhase-IIActiveF32015nonono
tocilizumabWhole mAbApprovedActiveIL6R2004nonono
tomaralimabWhole mAbPhase-IIActiveTLR22018nonono
tomuzotuximabWhole mAbPhase-IIActiveEGFR2016noYESYES
toripalimabWhole mAbApprovedActivePDCD12018YESnono
tosatoxumabWhole mAbPhase-IIIActivetoxin A2013nonono
tovetumabWhole mAbPhase-IIDiscontinuedPDGFRA2013nonono
tralokinumabWhole mAbPhase-IIIActiveIL132009YESnono
trastuzumabWhole mAbApprovedNFDERBB21997YESYESYES
tregalizumabWhole mAbPhase-IIDiscontinuedCD42010nonono
tremelimumabWhole mAbPhase-IIIActiveCTLA42005YESnono
trevogrumabWhole mAbPhase-IIActiveMSTN2015nonono
ublituximabWhole mAbPhase-IIIActiveMS4A12010nonono
ulocuplumabWhole mAbPhase-I/IIActiveCXCR42013nonono
urelumabWhole mAbPhase-IIActiveTNFRSF92010YESnono
ustekinumabWhole mAbApprovedActiveIL12B2008YESnono
utomilumabWhole mAbPhase-IIActiveTNFRSF92016YESnono
vadastuximabWhole mAb ADCPhase-IIIDiscontinuedCD332015nonono
valanafuspWhole mAb FusionPhase-IIActiveINSR2017noYESYES
vanalimabWhole mAbPhase-IActiveCD402017nonono
vantictumabWhole mAbPhase-IActiveFZD Family2013nonono
vanucizumabBispecific mAbPhase-IIDiscontinuedANGPT2;VEGFA2014YES;YESno;nono;YES
varisacumabWhole mAbPhase-II/IIIActiveVEGFA2016nonono
varlilumabWhole mAbPhase-IIActiveCD272014nonono
vatelizumabWhole mAbPhase-II/IIIActiveITGA22011nonono
vedolizumabWhole mAbApprovedActiveITGA4_ITGB72008nonono
veltuzumabWhole mAbPhase-IIActiveMS4A12007nonono
vesencumabWhole mAbPhase-IDiscontinuedNRP12010YESnono
vibecotamabBispecific Mixed mAb and scFvPhase-IActiveIL3RA;CD3E2018no;nono;nono;no
visilizumabWhole mAbPhase-IIIDiscontinuedCD3E2000nonono
vobarilizumabBispecific Single Domains (VH-VH')Phase-IIActiveIL6R;ALB2015no;nono;nono;no
vofatamabWhole mAbPhase-I/IIActiveFGFR32018nonoYES
volagidemabWhole mAbPhase-IIActiveGCCR2018noYESno
vonlerolizumabWhole mAbPhase-IIActiveTNFRSF42015YESnono
vopratelimabWhole mAbPhase-IIActiveICOS2017nonono
vorsetuzumabWhole mAb ADCPhase-IDiscontinuedCD702012nonono
vunakizumabWhole mAbPhase-I/IIActiveIL17A2016nonono
xentuzumabWhole mAbPhase-IIActiveIGF1&IGF22015nonono
zalifrelimabWhole mAbPhase-IIActiveCTLA42018nonono
zalutumumabWhole mAbPhase-IIDiscontinuedEGFR2005nonono
zampilimabWhole mAbPhase-I/IIActiveTGM22018nonono
zanolimumabWhole mAbPhase-IIIDiscontinuedCD42004nonono
zatuximabWhole mAbPhase-IIActiveEGFR2012nonono
zenocutuzumabBispecific mAbPhase-IIActiveERBB3;ERBB22017YES;YESno;nono;no
zolbetuximabWhole mAbPhase-IIIActiveCLDN182017nonono
zolimumabWhole mAbApprovedDiscontinuedCD3E1988YESnono

Search again

>   About
  • Antibody- and Nanobody-derived therapeutics with known sequences, and their structural coverage in the PDB.
  • Use the 'Get all therapeutics' tab to get a list of all immunotherapeutics.
  • Search by name: Find a specific entry using its INN -mab or -fusp name.
  • Search by attribute: Find a subset of immunotherapeutics with particular attributes. Choose from format, target, highest clinical trial reached, development status, year INN proposed, or structural coverage (or any combination).
  • Search by sequence: Find therapeutics near to your query sequence over any Chothia-defined region of the heavy and/or light chain variable domain sequence.
  • For more help, see the About page.
  • If you believe we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk
>   Search for a specific therapeutic
Please type a therapeutic INN name:
>   Search therapeutics by attribute
Therapeutic format:
Year INN Proposed:
Highest Clinical Trial:
Developmental Status:
Target:
Restrict to Known Structures:
>   Search for therapeutics by sequence similarity
Heavy chain sequence:
Light chain sequence:
Max No. of Therapeutics to be returned:
Minimum sequence identity:
Region to consider:
>   Downloads

Thera-SAbDab tracks all WHO-recognised Antibody- and Nanobody-derived therapeutics with released sequences.

Download all the therapeutic sequences we are currently tracking: xlsx / csv

Download all therapeutic sequences/structures including PL121: xlsx / csv

Download a list of all tracked therapeutics without sequence data: xlsx / csv

If you believe we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]